# Italy Rapid Diagnostics Market > Italy Rapid Diagnostics Market Research Report: Size, Share, Trend Analysis By Applications (Blood Glucose Testing, Infectious Disease Testing, Cardiometabolic Testing, Pregnancy Fertility Testing, Fecal Occult Blood Testing, Coagulation Testing, Toxicology Testing) and By Product Type (Over the Counter (OTC) Kits, Professional Kits) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.8% - **2024:** $ 943.29 Million - **2025:** $ 1,026.3 Million - **2035:** $ 2,385.42 Million - **Key Players:** Abbott Laboratories (US), Roche Diagnostics(CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), bioMérieux (FR), Cepheid (US), Hologic, Inc. (US), Ortho Clinical Diagnostics (US) **Report ID:** MRFR/MED/43668-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/italy-rapid-diagnostics-market-45348 --- ## Market Summary ## **Italy Rapid Diagnostics Market Overview** As per MRFR analysis, the Italy Rapid Diagnostics Market Size was estimated at 578.0 (USD Million) in 2023. The Italy Rapid Diagnostics Market Industry is expected to grow from 628.0 (USD Million) in 2024 to 1,261.0 (USD Million) by 2035. The Italy Rapid Diagnostics Market CAGR (growth rate) is expected to be around 6.543% during the forecast period (2025 - 2035). ## **Key Italy Rapid Diagnostics Market Trends Highlighted** The Italy Rapid Diagnostics Market is growing exceptionally fast because there is a greater need for effective testing solutions during and after health crises. Major contributors to the market include the increasing incidence of infectious diseases and higher attention toward preventative medicine. Italian authorities have underlined the increasing need for early detection and swift medical intervention, thus creating further demand for rapid diagnostics in clinics and within the domiciliary environment. In addition, the public awareness concerning health issues and the application of rapid diagnostic methods, including PCR and Antigen tests, have greatly amplified during the COVID-19 pandemic in Italy with a plethora of diseases. Possibilities to be developed in the market are the use of rapid diagnostics in new fields like telemedicine and personalized medicine. Technological advancements provide an opportunity for Italian manufacturers to use digital channels that provide patients with easier access to rapid diagnostics and facilitate timely action. Another possibility for better accuracy and efficiency in test results is the use of [**artificial intelligence**](../../../reports/healthcare-artificial-intelligence-market-5681) in the diagnostic processes. Recently, there has been a significant move towards [**point-of-care testing**](../../../reports/point-of-care-diagnostics-testing-market-10642), which tests and diagnoses patients without using traditional laboratory facilities, thereby improving turnaround time. The Italian healthcare system is increasingly using remote testing for patients living in outlying areas to facilitate access to testing results. Furthermore, public-private partnerships in Italy have designed new rapid diagnostic tests to meet global healthcare demands and local supply needs. As such, these changes support the idea of Italy being an advanced center for rapid diagnostics and improving health services for the population. ## **Italy Rapid Diagnostics Market Drivers** ### **Increase in Chronic Diseases** The rising prevalence of chronic diseases in Italy is a significant driver for the Italy Rapid Diagnostics Market Industry. According to the Italian Ministry of Health, around 24 million Italians are currently suffering from chronic conditions such as diabetes, cancer, and cardiovascular diseases. With the Italian National Health Service prioritizing early diagnosis and management of these conditions, the demand for rapid diagnostic tools is expected to rise. As evidenced by a growing emphasis on point-of-care testing solutions advocated by the Italian Society of Medicine, rapid diagnostics can lead to timely interventions, which in turn can improve patient outcomes and optimize healthcare resources. Furthermore, as healthcare providers seek to meet the demands of an aging population, the market for rapid diagnostics is set to expand significantly. ### **Technological Advancements** Technological advancements in diagnostic testing are fueling the growth of the Italy Rapid Diagnostics Market Industry. Innovations such as portable diagnostic devices and automated lab systems streamline the testing process, enabling faster and more accurate results. For instance, initiatives by Italian biotech firms have led to the development of new rapid tests capable of detecting various diseases within minutes, enhancing the capabilities of **healthcare systems**. According to the Italian Federation of Medical Technology, investments in health technology are expected to increase by 10% annually, reflecting the urgency to adopt more efficient diagnostic methods amidst the ongoing push for improved patient care. ### **Government Initiatives and Funding** The Italian government is actively supporting initiatives aimed at enhancing the healthcare system, which directly boosts the demand for rapid diagnostics. Recent policy changes include increased funding for healthcare innovations, particularly in response to the COVID-19 pandemic, where rapid testing proved essential. The Ministry of Health’s allocation of resources for research and development in rapid diagnostics fosters an environment conducive to growth. Moreover, partnerships with established organizations like the Italian Red Cross have promoted the use of rapid diagnostic tests in various healthcare settings, ensuring widespread accessibility and reliability. As this collaboration continues, the rapid diagnostics market is likely to see sustained growth and improved public health outcomes. ### **Rising Health Awareness** There is an increasing health consciousness among the Italian population, leading to heightened demand for quick and reliable diagnostic tools. Campaigns led by healthcare organizations and public health entities are promoting early disease detection and prevention measures. Data shows that over 70% of Italians now engage in regular health check-ups, emphasizing the importance of rapid diagnostics for maintaining health. This cultural shift towards preventive healthcare is supported by the Italian Ministry of Health, which encourages citizens to participate in routine screenings. As awareness grows, so does the need for innovative diagnostic solutions, thereby enhancing the prospects for the Italy Rapid Diagnostics Market Industry. ## **Italy Rapid Diagnostics Market Segment Insights** ### **Rapid Diagnostics Market Application Insights** The Italy Rapid Diagnostics Market is characterized by a diverse range of applications, contributing significantly to its overall performance. Among these applications, Blood Glucose Testing stands out due to the growing prevalence of diabetes across Italy, prompting a demand for efficient and rapid testing solutions. Infectious Disease Testing also plays a crucial role, particularly in light of recent public health challenges, as it aids in the early detection and management of diseases, thus enhancing patient outcomes and streamlining treatment processes. Cardiometabolic Testing is gaining traction with the rising awareness of cardiovascular health, leading to a need for regular monitoring of related parameters. Additionally, Pregnancy Fertility Testing remains a significant aspect of the market as it supports family planning and reproductive health initiatives, demonstrating its importance in both personal and public health contexts. Fecal Occult Blood Testing is crucial for colorectal cancer screening and early detection, leveraging the increasing focus on preventive healthcare measures in Italy. Coagulation Testing is also fundamental in the management of various medical conditions, ensuring timely intervention and monitoring, which is vital in surgical and therapeutic scenarios. Lastly, Toxicology Testing serves an essential function in forensic science and drug testing, addressing public safety concerns and supporting legal systems. Overall, these applications together reflect a comprehensive landscape of the Italy Rapid Diagnostics Market, underpinned by a growing emphasis on health monitoring and disease prevention in the region. The market is not only expanding in value but also evolving in relevance as healthcare priorities shift towards proactive and rapid diagnostic solutions. ### **Rapid Diagnostics Market Product Type Insights** The Italy Rapid Diagnostics Market has showcased significant growth trends, with the Product Type segment playing a crucial role in its expansion. The rising awareness regarding healthcare and the convenience associated with testing have led to the increased utilization of Over the Counter (OTC) Kits among the general population. These kits empower consumers by providing easy access to diagnostic tools that can be used at home, thus driving demand for at-home testing solutions. On the other hand, Professional Kits are essential in clinical and hospital settings, supporting healthcare professionals in delivering timely and accurate diagnoses for various conditions. This dual presence of both OTC Kits and Professional Kits highlights the diverse needs and preferences of end-users in Italy's healthcare landscape. With ongoing advancements in technology, both segments are likely to experience further innovation, enhancing their effectiveness and user experience. The combination of these product types caters to a broad spectrum of healthcare requirements, making them integral to the overall growth and efficiency of the Italy Rapid Diagnostics Market. ## **Italy Rapid Diagnostics Market Key Players and Competitive Insights** The Italy Rapid Diagnostics Market is characterized by a dynamic competitive landscape, driven by a combination of increasing consumer demand for quick and accurate testing methods, growing investments in healthcare technology, and a strong emphasis on early disease detection and management. In this context, various players operate within the market, showcasing a diverse range of products and solutions aimed at improving diagnostic speed and accuracy across numerous health conditions. The market dynamics are further shaped by regulatory frameworks, local healthcare system requirements, and the presence of innovative technologies that facilitate real-time testing and results. As the healthcare sector continues to evolve, established companies and new entrants alike are continually adapting their strategies to capture market share while addressing the changing needs of healthcare providers and patients in Italy. BioMerieux has made significant strides in the Italy Rapid Diagnostics Market, leveraging its robust technological capabilities and extensive experience in the field of in vitro diagnostics. The company is recognized for its innovative solutions that cater to various medical testing needs, including infectious diseases, cancer, and cardiovascular ailments. BioMerieux’s strengths lie in its ability to provide reliable, rapid test results that healthcare professionals can seamlessly integrate into their clinical workflows. The firm invests heavily in research and development, which has led to the introduction of several advanced diagnostic solutions that resonate well with the Italian healthcare system, reinforcing its reputation as a trusted provider. Furthermore, BioMerieux's strategic partnerships and collaborations with local healthcare entities further enhance its market presence, ensuring its products remain at the forefront of the rapidly evolving diagnostics sector in Italy. Johnson and Johnson holds a prominent position in the Italy Rapid Diagnostics Market, where it offers a comprehensive portfolio of diagnostic products and services that cater to a wide array of healthcare needs. The company is known for its innovative testing solutions, which include point-of-care testing devices and laboratory-based diagnostic assays. Johnson and Johnson's strengths in the Italian market are bolstered by its commitment to quality and compliance with stringent regulatory standards, making it a reliable choice for healthcare providers. Moreover, the company's strategic mergers and acquisitions have fortified its market stance, allowing it to expand its technological capabilities and product offerings. Through targeted investments in the region, Johnson and Johnson continues to enhance its service delivery and support healthcare institutions in Italy, driving improvements in patient outcomes and diagnostic efficiency. ### **Key Companies in the Italy Rapid Diagnostics Market Include** - BioMerieux - Johnson and Johnson - Medtronic - Qiagen - PerkinElmer - Eli Lilly - Hologic - Sysmex - Thermo Fisher Scientific - Ortho Clinical Diagnostics - Roche - Siemens Healthineers - Abbott Laboratories - Cepheid - BD ## **Italy Rapid Diagnostics Market Industry Developments** The Italy Rapid Diagnostics Market has been experiencing notable developments, with a growing emphasis on innovative testing solutions amid healthcare advancements. Companies like Roche and Abbott Laboratories have intensified their focus on enhancing rapid diagnostic tests, catering to the rising demand for timely and accurate results in various medical conditions, particularly in infectious diseases. In September 2023, BioMerieux unveiled a pioneering rapid diagnostic assay aimed at significantly improving the speed of pathogen detection, reflecting a trend towards automation and real-time testing. Current affairs indicate active collaboration between local healthcare authorities and major players, exemplified by a partnership involving Hologic and Thermo Fisher Scientific to bolster COVID-19 testing capabilities. The market's valuation has been positively impacted, with several companies, including Johnson Johnson and Siemens Healthineers, reporting substantial revenue growth driven by increased adoption of rapid diagnostic technologies. Furthermore, in June 2023, Qiagen announced the acquisition of a local diagnostics firm, aimed at expanding its product portfolio and enhancing its market share in Italy. These instances illustrate a dynamic landscape within the Italy Rapid Diagnostics Market, characterized by innovation, collaboration, and strategic expansions. ## **Italy Rapid Diagnostics Market Segmentation Insights** ### **Rapid Diagnostics Market Application Outlook** - Blood Glucose Testing - Infectious Disease Testing - Cardiometabolic Testing - PregnancyFertility Testing - Fecal Occult Blood Testing - Coagulation Testing - Toxicology Testing ### **Rapid Diagnostics Market Product Type Outlook** - Over the Counter (OTC) Kits - Professional Kits ## Market Drivers ### Supportive Regulatory Environment The regulatory landscape in Italy is becoming increasingly supportive of innovations in the rapid diagnostics market. Regulatory bodies are streamlining approval processes for new diagnostic tests, which encourages research and development in this sector. This supportive environment is crucial for fostering innovation and ensuring that new diagnostic solutions reach the market swiftly. Recent initiatives by the Italian Medicines Agency (AIFA) aim to expedite the evaluation of rapid diagnostic tests, thereby enhancing their availability to healthcare providers and patients. As a result, the rapid diagnostics market is likely to experience accelerated growth, driven by the introduction of novel diagnostic tools that meet regulatory standards and address the needs of the healthcare system. ### Rising Consumer Awareness and Demand Consumer awareness regarding health and wellness is significantly impacting the rapid diagnostics market in Italy. As individuals become more informed about their health, there is a growing demand for accessible and reliable diagnostic solutions. This trend is particularly evident in the increasing popularity of home testing kits, which allow consumers to monitor their health conveniently. Market Research Future suggests that the home testing segment is anticipated to grow by 15% annually, reflecting a shift in consumer behavior towards proactive health management. This heightened awareness is prompting manufacturers to innovate and expand their product offerings in the rapid diagnostics market, catering to the evolving needs of health-conscious consumers. ### Growing Prevalence of Chronic Diseases The rising incidence of chronic diseases in Italy is a pivotal driver for the rapid diagnostics market. As the population ages, conditions such as diabetes, cardiovascular diseases, and respiratory disorders become more prevalent. This trend necessitates timely and accurate diagnostic solutions to manage these health issues effectively. According to recent data, chronic diseases account for approximately 80% of healthcare costs in Italy, underscoring the urgent need for rapid diagnostics. The ability to quickly identify and monitor these conditions can lead to better patient outcomes and reduced healthcare expenditures. Consequently, healthcare providers are increasingly investing in rapid diagnostic tools to enhance disease management and improve patient care, thereby propelling the growth of the rapid diagnostics market in Italy. ### Technological Integration in Healthcare The integration of advanced technologies in healthcare is transforming the rapid diagnostics market in Italy. Innovations such as artificial intelligence, machine learning, and telemedicine are enhancing the accuracy and efficiency of diagnostic tests. These technologies enable healthcare professionals to analyze data more effectively, leading to quicker decision-making processes. For instance, AI-driven diagnostic tools can process vast amounts of data to identify patterns that may not be immediately apparent to human analysts. This technological evolution is expected to increase the adoption of rapid diagnostic solutions, as healthcare providers seek to improve patient care and operational efficiency. The market is projected to witness a growth rate of approximately 12% annually, driven by these technological advancements. ### Increased Focus on Preventive Healthcare There is a notable shift towards preventive healthcare in Italy, which significantly influences the rapid diagnostics market. This paradigm shift emphasizes early detection and intervention, aiming to reduce the burden of diseases before they escalate. The Italian government has been promoting health awareness campaigns that encourage regular screenings and check-ups. As a result, the demand for rapid diagnostic tests that facilitate early disease detection is on the rise. Market data indicates that the preventive healthcare segment is expected to grow at a CAGR of around 10% over the next five years. This trend not only enhances patient health outcomes but also reduces long-term healthcare costs, thereby driving investments in the rapid diagnostics market. ## Future Outlook The [Rapid Diagnostics Market](https://www.marketresearchfuture.com/reports/rapid-diagnostics-market-11687) is projected to grow at an 8.8% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for point-of-care testing, and rising healthcare expenditure. **New opportunities:** - Development of portable diagnostic devices for remote areas - Integration of AI in diagnostic tools for enhanced accuracy - Expansion of [telehealth](https://www.marketresearchfuture.com/reports/telehealth-market-900)services incorporating rapid testing solutions By 2035, the market is expected to achieve substantial growth, driven by innovation and strategic investments. ## Segment Insights ### By Product: Over-the-Counter (OTC) Kits (Largest) vs. Professional Kits (Fastest-Growing) The market share distribution in the Italy rapid diagnostics market reveals that Over-the-Counter (OTC) Kits hold a significant share, making them the leading choice among consumers. Professional Kits, while smaller in market presence, are gaining traction rapidly as healthcare professionals increasingly adopt them for diagnostic purposes. The ease of access provided by OTC Kits continues to appeal to consumers, solidifying their market dominance. Growth trends indicate that OTC Kits will continue to be the preferred option due to their convenience, while Professional Kits are projected to rise significantly over the next few years. Factors driving this growth include increased health awareness, the rise of home testing, and advancements in diagnostic technologies that enhance the effectiveness of Professional Kits in clinical settings. Over-the-Counter (OTC) Kits (Dominant) vs. Professional Kits (Emerging) Over-the-Counter (OTC) Kits are characterized by their ease of use, accessibility, and consumer-friendly nature, allowing individuals to conduct tests at home without professional supervision. Their established presence and strong consumer trust make them the dominant force in the market. In contrast, Professional Kits are emerging as significant market players, especially in clinical environments, where precision and reliability are paramount. These kits often incorporate advanced technologies, catering to professional diagnostic needs with higher accuracy and detailed analysis, thus attracting healthcare providers as the awareness of their capabilities continues to grow. ### By Application: Blood Glucose Testing (Largest) vs. Infectious Disease Testing (Fastest-Growing) In the Italy rapid diagnostics market, Blood Glucose Testing holds a significant share, driven by the increasing prevalence of diabetes and the need for regular monitoring. Infectious Disease Testing is emerging rapidly as public health concerns rise, fueled by ongoing needs for early detection and management of infectious diseases, particularly post-pandemic. As healthcare continues to evolve, advancements in technology and increased consumer awareness contribute to growth in the market. The trend towards home diagnostics is particularly notable, with individuals seeking convenient and quick testing methods. Additionally, supportive healthcare policies and investments in healthcare infrastructure are accelerating the adoption of various diagnostic tests across the segment. Blood Glucose Testing: Dominant vs. Infectious Disease Testing: Emerging Blood Glucose Testing remains a dominant player in the Italy rapid diagnostics market, characterized by its integration into daily management for diabetes patients. With a robust infrastructure and strong consumer trust, this segment benefits from a well-established product range and continuous innovation in monitoring technology. In contrast, Infectious Disease Testing is rapidly emerging, driven by advancements in rapid testing technologies and a heightened focus on public health safety. This segment is bolstered by increasing demand for quick results and enhanced accuracy, particularly in pandemic contexts. Collectively, these segments illustrate the diverse landscape of the Italy rapid diagnostics market, catering to both chronic and acute health needs. ## Competitive Benchmarking The rapid diagnostics market in Italy is characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for timely diagnostic solutions. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are at the forefront, each adopting distinct strategies to enhance their market presence. Abbott Laboratories (US) focuses on innovation, particularly in point-of-care testing, which aligns with the growing trend towards decentralized healthcare. Roche Diagnostics (CH) emphasizes partnerships and collaborations to expand its diagnostic portfolio, while Siemens Healthineers (DE) is investing heavily in digital transformation to streamline operations and improve diagnostic accuracy. Collectively, these strategies contribute to a competitive environment that is increasingly centered on technological innovation and strategic partnerships. In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several key players exerting influence. This fragmentation allows for a diverse range of products and services, catering to various segments of the healthcare market. The collective actions of these companies indicate a trend towards consolidation, as they seek to leverage synergies and enhance their competitive positioning. In October 2025, Roche Diagnostics (CH) announced a strategic partnership with a leading Italian healthcare provider to enhance the accessibility of its rapid diagnostic tests across the country. This collaboration is expected to improve patient outcomes by ensuring that advanced diagnostic solutions are readily available in both urban and rural settings. The strategic importance of this partnership lies in Roche's commitment to expanding its market reach while addressing the specific needs of the Italian healthcare system. In September 2025, Siemens Healthineers (DE) launched a new digital platform aimed at integrating artificial intelligence into its diagnostic processes. This platform is designed to enhance the accuracy and speed of diagnostics, thereby improving patient care. The introduction of AI-driven solutions signifies a pivotal shift towards more personalized and efficient healthcare delivery, positioning Siemens as a leader in the digital transformation of diagnostics. In August 2025, Abbott Laboratories (US) unveiled a new rapid testing device that utilizes advanced biosensor technology to deliver results in under 15 minutes. This innovation not only addresses the demand for speed in diagnostics but also reflects Abbott's ongoing commitment to research and development. The strategic importance of this launch is underscored by the potential to capture a larger market share in the rapidly evolving diagnostics landscape. As of November 2025, current trends in the rapid diagnostics market include a pronounced focus on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift suggests that companies that prioritize these areas will be better positioned to thrive in the rapidly changing market. ## Recent News & Developments The Italy Rapid Diagnostics Market has been experiencing notable developments, with a growing emphasis on innovative testing solutions amid healthcare advancements. Companies like Roche and Abbott Laboratories have intensified their focus on enhancing rapid diagnostic tests, catering to the rising demand for timely and accurate results in various medical conditions, particularly in infectious diseases. In September 2023, BioMerieux unveiled a pioneering rapid diagnostic assay aimed at significantly improving the speed of pathogen detection, reflecting a trend towards automation and real-time testing. Current affairs indicate active collaboration between local healthcare authorities and major players, exemplified by a partnership involving Hologic and Thermo Fisher Scientific to bolster COVID-19 testing capabilities. The market's valuation has been positively impacted, with several companies, including Johnson Johnson and Siemens Healthineers, reporting substantial revenue growth driven by increased adoption of rapid diagnostic technologies. Furthermore, in June 2023, Qiagen announced the acquisition of a local diagnostics firm, aimed at expanding its product portfolio and enhancing its market share in Italy. These instances illustrate a dynamic landscape within the Italy Rapid Diagnostics Market, characterized by innovation, collaboration, and strategic expansions. ## Report Scope | MARKET SIZE 2024 | 943.29(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1026.3(USD Million) | | MARKET SIZE 2035 | 2385.42(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.8% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Danaher Corporation (US), Becton Dickinson and Company (US), bioMérieux (FR), Cepheid (US), Hologic, Inc. (US), Ortho Clinical Diagnostics (US) | | Segments Covered | Product, Application | | Key Market Opportunities | Emergence of innovative technologies enhancing speed and accuracy in the rapid diagnostics market. | | Key Market Dynamics | Technological advancements drive rapid diagnostics adoption, enhancing patient outcomes and reshaping healthcare delivery in Italy. | | Countries Covered | Italy | ## Frequently Asked Questions **Q: What was the overall market valuation of the rapid diagnostics market in Italy in 2024?** A: The overall market valuation was $943.29 Million in 2024. **Q: What is the projected market valuation for the rapid diagnostics market in Italy by 2035?** A: The projected valuation for 2035 is $2385.42 Million. **Q: What is the expected CAGR for the rapid diagnostics market in Italy during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 8.8%. **Q: Which companies are considered key players in the Italy rapid diagnostics market?** A: Key players include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific. **Q: What were the revenue figures for Over-the-Counter (OTC) Kits in 2024?** A: The revenue for Over-the-Counter (OTC) Kits was $376.32 Million in 2024. **Q: What is the projected revenue for Professional Kits in the rapid diagnostics market by 2035?** A: The projected revenue for Professional Kits by 2035 is $1435.42 Million. **Q: How much revenue did Blood Glucose Testing generate in 2024?** A: Blood Glucose Testing generated $150.0 Million in revenue in 2024. **Q: What is the expected revenue range for Infectious Disease Testing by 2035?** A: The expected revenue range for Infectious Disease Testing by 2035 is $300.0 Million to $800.0 Million. **Q: What was the revenue for Cardiometabolic Testing in 2024?** A: Cardiometabolic Testing had a revenue of $200.0 Million in 2024. **Q: What is the projected revenue for Fecal Occult Blood Testing by 2035?** A: The projected revenue for Fecal Occult Blood Testing by 2035 is between $80.0 Million and $200.0 Million. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/italy-rapid-diagnostics-market-45348*